Results 161 to 170 of about 1,285,117 (188)

A Novel SXXLF Motif in the FXR N‐Terminal Domain Mediates Coregulator and Interdomain Interactions

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
Farnesoid X receptor (FXR)‐N‐terminal domain (NTD) regulates transcriptional activity through interdomain communication with the LBD and is also involved in co‐activator recruitment. The SENLF motif is the first defined functional element within the FXR‐NTD and mediates both NTD–LBD interaction and selective co‐activator engagements to drive NTD ...
Priscilla Villalona, Thilini Pulahinge, Tracy Yu, Jordan Wenning, Sabab Hasan Khan, Crawford Joseph Frisbie, Jill Magafas, Addison Barbe, C. Denise Okafor   +8 more
wiley   +1 more source

Comparison of Guideline‐Directed Medical Therapy in Black versus White Patients With Heart Failure With Reduced Ejection Fraction in a Large, Integrated Health Care System

Clinical Cardiology, Volume 49, Issue 9, September 2026.
Using real‐world data, this study identified differences in recommended GDMT treatment between Black and White HFrEF patients. Black patients were more likely to be treated with MRAs than White patients. Among those treated with GDMT, Black patients were more likely to be treated to target with ACEi/ARB/ARNis and MRAs.
Natalia C. Berry, Yi‐Shin Sheu, Karen Chesbrough, R. Clayton Bishop, Suma Vupputuri   +4 more
wiley   +1 more source

Prospective Evaluation of Quality‐of‐Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION‐HF 12‐Month Results

Clinical Cardiology, Volume 49, Issue 9, September 2026.
Among patients with HFrEF, initiation of dapagliflozin resulted in significant improvements in quality of life, as demonstrated by increased KCCQ‐23 scores during follow‐up. ABSTRACT Introduction Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge ...
Victoria Potoupni, Aristi Boulmpou, Spyridon Maragkoudakis, Alexandros Briasoulis, Emmanouil Foukarakis, Alexia Stavrati, Konstantinos Papadopoulos, Katerina K. Naka, Anna Kotsia, Ioannis Parissis, Antonios Ziakas, Stamatis Adamopoulos, Dimitrios Tziakas, Sotirios Patsilinakos, Melanie Konstantinidou, Periklis Davlouros, Zacharias Christogiannis, Konstantinos Tsitlakidis, Ioannis Pantelakis, Georgios Stefanakis, Marios Kolios, Ioannis Baltogiannis, Evangelos Voltyrakis, Christos Varounis, Andreas Samothrakitis, Dimitrios Krikidis, Panagiotis Tsialoukis, Zoe Paparepa, Dimitrios Gourlis, Nikolaos Papoutsidakis, Apostolos Karavidas, Christodoulos Papadopoulos   +31 more
wiley   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed, Abdinasir Adam Shidane, Abdullahi Mohamud Abdiasis, Mohamed Hassan Hussein, Ayaanle Osman Ibrahim, Anas Ali Abdi, Kowthar Ismail Hashi, Mohamed Abdullahi Mohamud, Ali Jimale Mohamed   +8 more
wiley   +1 more source

Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P‐gp Inhibitor

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Balcinrenone (AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist with a distinct mode of action being developed as a fixed‐dose combination with the sodium–glucose cotransporter‐2 inhibitor dapagliflozin for the treatment of heart failure with impaired kidney function, and chronic kidney disease.
Anna L. Eriksson, Deeyen Karsanji, Amy H. Shi, Joanna Parkinson, Maria Heijer, Edward Austin, Bosse Lindmark, Charlotta Vedin‐Nilsson, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +10 more
wiley   +1 more source

Metabolic Syndrome: From Mechanisms to Therapeutic Interventions

MedComm, Volume 7, Issue 9, September 2026.
A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Dengue Virus Molecular Targets and Antiviral Drug Development: Advances, Challenges and Therapeutic Perspectives

ChemistrySelect, Volume 11, Issue 33, 1 September 2026.
This narrative review analyzes DENV molecular targets, including structural proteins (C, prM/M, E), non‐structural components (NS1NS5), and host factors, alongside small‐molecule candidates in preclinical and clinical phases. Owing to high structural conservation, the NS2B‐NS3 protease and NS5 (RdRp/MTase) remain primary drug discovery focuses, while ...
Aryane Lucia da Silva Aguiar De Oliveira, José Arion Da Silva Moura, Pedro César de Souza, Marcelo Arthur Dias da Costa Santana, Matheus Vinicius Guimarães de Melo, Douglas Carvalho Francisco Viana, Marina Galdino Da Rocha Pitta, Isabella Luiza Ralph de Oliveira, Maira Galdino Da Rocha Pitta   +8 more
wiley   +1 more source

Corticosteroid Receptor Modulation in the Dorsal Striatum Prevents Morphine‐Induced Place Preference and Reduction in Dopamine Transporter (DAT) Immunoreactivity in Rats

Addiction Biology, Volume 31, Issue 9, September 2026.
Intra‐dorsal striatal corticosterone attenuated morphine‐induced CPP. GR and MR antagonists also attenuated morphine‐induced CPP. Morphine reduced DAT immunoreactivity, an effect prevented by CORT and antagonists. Distinct corticosteroid manipulations converged on similar reward and DAT outcomes.
Payman Raise‐Abdullahi, Fatemeh Rezamohammadi, Mehrnoush Rahmani, Abbas Ali Vafaei, Roghayeh Pakdel, Hamed Rashidipour, Ali Rashidy‐Pour   +6 more
wiley   +1 more source

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT Aim Patients with chronic kidney disease (CKD) have an increased cardiovascular risk. Since neutrophils and neutrophil‐borne proteins contribute to cardiovascular disease, we analyzed the neutrophil phenotype in patients with CKD who presented with a spectrum of cardiovascular comorbidities.
Sonja Vondenhoff, Alessandra Antwerpen, Carolina Victoria Cruz Junho, Philipp Martin, Sina Hourtz, Jinmi Zou, Berkan Kurt, Carolin Haas, Susanne Fleig, Corinna Schulte, Jane Lauxen, Martina Wessiepe, Ulrike Späte‐Schulze, Rafael Kramann, Jürgen Floege, Oliver Soehnlein, Joachim Jankowski, Claudia Goettsch, Yvonne Döring, Florian Kahles, Nikolaus Marx, Constance C. F. M. J. Baaten, Heidi Noels   +22 more
wiley   +1 more source